Royalty Pharma (RPRX) Short-term Investments (2019 - 2026)

Royalty Pharma has reported Short-term Investments for 8 years, with the latest figure at $21.9 million in Q1 2026.

• Quarterly Short-term Investments rose 80.99% year-over-year to $21.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.9 million (up 80.99% YoY) and the FY2025 annual result came in at $18.8 million, down 67.7% from the prior year.
• Short-term Investments improved to $21.9 million in Q1 2026 per RPRX's latest filing, from $18.8 million in the prior quarter.
• Over five years, Short-term Investments peaked at $409.3 million in Q3 2022 and troughed at $5.3 million in Q3 2023.
• A 5-year average of $76.1 million and a median of $24.4 million in 2022 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments plunged 98.71% in 2023, then surged 815.09% in 2024.
• Over 5 years, Short-term Investments stood at $24.4 million in 2022, then slipped by 25.06% to $18.3 million in 2023, then surged by 218.03% to $58.2 million in 2024, then tumbled by 67.7% to $18.8 million in 2025, then advanced by 16.49% to $21.9 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $21.9 million, $18.8 million, and $16.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.